Brief: Acura Pharmaceuticals came to co's attention it previously inadvertently disclosed to an analyst information not previously publicly disclosed by co

Acura Pharmaceuticals

11/03/2016 21:14

March 11 (Reuters) - Acura Pharmaceuticals Inc  ACUR.O : 
 * Came to co's attention it previously inadvertently disclosed to an analyst 
   information not previously publicly disclosed by co 
 * 1 of slides contained information on 1 possible development timeline and 
   possible costs associated with Limitx 
 * Believes the information contained therein was consistent with but more 
   detailed than its previous disclosure 
 * Intends to update market with a development plan after a meeting FDA assuming 
   success from results from study AP-LTX-400 
 * Disclosed potential market opportunity for products based on an illustrated 
   10% market share, is not based on mgmts expectations 
 
* Source text for Eikon (1.usa.gov/1YHzw3f) 
* Further company coverage  ACUR.O  ((Bengaluru Newsroom; +1 646 223 8780))